xi

Being a leading manufacturer of natural ingredients and nutrition supplements in China, HSF focuses on the R&D, production, and marketing of Natural Vitamin E and Phytosterol, Ferulic acid and Gamma Oryzanol throughout the worldwide market, with its headquarter located in the city of Xi"an, Shaanxi province, southwest China.

xi

Shou Bai CHAO, became executive director on June 22, 2018 and Chief Operating Officer（COO）on May 1, 2018. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years" experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018, and was president and the Board Director at the Chinese Biopharmaceutical Association-USA from June 2014 to June 2016.

Dongxu QIU, a co-founder of our company. He was appointed as an executive director on January 13, 2009, and has served as senior vice president since January 2009. He is primarily responsible for advising on the business and strategic development of our company. Dr. Qiu has around 25 years" experience in the biotechnology industry. Dr. Qiu has led several rounds of corporate financing as well as the technology transfers . From January 1993 to April 1997, he was a research scientist at Biomira. Inc. From 1999 to 2000, he served as associate director of product operations at Altarex Inc., responsible for analytical development and product formulation. Dr. Qiu became head of scientific operations at ARIUS Research Inc. from 2000 to 2002, president of Asia at MDS Capital from May 2003 to September 2005, deputy general manager at Shanghai Jima Pharmaceutical Technology Co., Ltd. from 2006 to 2009, and general manager at ChinaBio LLC from March 2007 to April 2011.

Liesheng CHEN, was appointed vice president at the Production Centre. He graduated from East China University of Science and Technology and has 30 years" experience in biological products production management. He formerly worked at the Shanghai Institute of Biological Products research center, Shanghai Rongsheng Biotech CO., LTD., and Walvax Biotechnology Co., Ltd. where he participated in a number of vaccine research projects as well as carrying out developmental and industrialisation work.

Xiaoman DONG was appointed as vice president of the Quality Management.Mrs. Donghas impressive experience in the area of biological product quality management. Shehas overseen several vaccine quality management projects, including 15 GMP certifications and re-certifications of vaccine products.In addition, shesuccessfullyled quality management for multiple vaccine bulks and freeze-dried preparation workshops, as well as the design, construction, verification and production operation.Mrs. Dongused to hold senior positions at the Lanzhou Institute of Biological Products, Beijing Tiantan Biological Products Co. Ltd., Jiangsu Walvax Biotech Company, etc., She holds a degree fromXi"an Jiao Tong University.

Yonghui WU was appointed as vice president of the Marketing Department. With nearly 25 years of experience in the bio-pharmaceutical market,Yonghui Wu has a keen market sense which allows him to effectively grasp market dynamics and direction. He also has excellent coordination, communication, media management and public relation skills.Mr. Wu used to work at Sanofi-Pasteur, Beijing Novartis Pharma, Beijing Boya Wei-ming United Stem Cell Technology Co., Ltd., Beijing Renhe Huatai Technology Co., Ltd., Beijing Origincell Biotechnology Co., Ltd., Liaoning Aimei Bio-vaccine Co., Ltd., and other top enterprises. During his service at Sanofi-Pasteur, he formed and managed a team of more than 60 people, achieved successive increase in regional sales over four years.Mr. Wu has a master"s degree in business administration from the University of International Business and Economics, and a bachelor"s degree in preventive medicine from Beijing Medical University.

Yunli XU was appointed as vice president of vaccine research and development in 2020. He is in charge of the R&D of viral and genetic products, as well as the construction and management of GMP pilot plants. With over 30 years of experience in the field of biotechnology, Mr. Xu has led multiple pre-clinical trial projects on gene therapy and is proficient in GMP pilot plant design, sample preparation and manufacturing verification. He used to serve as director in the NIP Pharm and general manager in Vector Gene Technology Company Ltd. Mr. Xu holds a degree of biology from Wuhan University and a degree of genetic engineering and molecular biology from Otsuka Pharmaceutical Co., Ltd.